TDC
CLDX icon

Thompson Davis & Co’s Celldex Therapeutics CLDX Stock Holding History

Thompson Davis & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-467
Closed -$110K – 1084
2015
Q4 		$110K Buy
+467
New +$102K 0.16% 150

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Thompson Davis & Co's CLDX Position: Q1 2016 in Review

Thompson Davis & Co sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 467 shares — an estimated $110K sold.

Thompson Davis & Co first reported a position in CLDX in Q4 2015 and held it in 1 quarter. The position peaked at $110K in Q4 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Thompson Davis & Co reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 467 Celldex Therapeutics shares in Q1 2016, an estimated $110K.
  • Thompson Davis & Co first reported a position in Celldex Therapeutics in Q4 2015 and held it in 1 quarter.
  • Thompson Davis & Co's Celldex Therapeutics position peaked at $110K in Q4 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.